Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11102-015-0692-z http://scihub22266oqcxt.onion/10.1007/s11102-015-0692-z C4799251!4799251 !26542280     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26542280 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26542280 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pituitary 2016 ; 19 (2 ): 138-48 Nephropedia Template TP {{tp|p=26542280 |t=2016. Osilodrostat, a potent oral 11?-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing s disease |pdf=|usr=}}{{26542280 }} gab.com Text Osilodrostat, a potent oral 11 -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing s disease JO: Pituitary http://www.kidney.de/pget.php?&tw=1&pmid=26542280 #FOAvip PURPOSE: In a 10-week proof-of-concept study (LINC 1), the potent oral 11?-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing's disease. The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cushing's disease. METHODS: Phase II, open-label, prospective study of two patient cohorts. Follow-up cohort: 4/12 patients previously enrolled in LINC 1, offered re-enrollment if baseline mean UFC was above ULN. Expansion cohort: 15 newly enrolled patients with baseline UFC > 1.5 × ULN. In the follow-up cohort, patients initiated osilodrostat twice daily at the penultimate efficacious/tolerable dose in LINC 1; dose was adjusted as needed. In the expansion cohort, osilodrostat was initiated at 4 mg/day (10 mg/day if baseline UFC > 3 × ULN), with dose escalated every 2 weeks to 10, 20, 40, and 60 mg/day until UFC ? ULN. Main efficacy endpoint was the proportion of responders (UFC ? ULN or ?50% decrease from baseline) at weeks 10 and 22. RESULTS: Overall response rate was 89.5% (n/N = 17/19) at 10 weeks and 78.9% (n/N = 15/19) at 22 weeks; at week 22, all responding patients had UFC ? ULN. The most common AEs observed during osilodrostat treatment were nausea, diarrhea, asthenia, and adrenal insufficiency (n = 6 for each). New or worsening hirsutism (n = 2) and/or acne (n = 3) were reported among four female patients, all of whom had increased testosterone levels. CONCLUSIONS: Osilodrostat treatment reduced UFC in all patients; 78.9% (n/N = 15/19) had normal UFC at week 22. Treatment with osilodrostat was generally well tolerated. Twit Text FOAVip Osilodrostat, a potent oral 11 -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing s disease ????Pituitary http://www.kidney.de/pget.php?&tw=1&pmid=26542280 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26542280 #FOAvip English Wikipedia <ref>{{Cite pmid|26542280 }}</ref> Osilodrostat, a potent oral 11?-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing s disease #MMPMID26542280 Fleseriu M ; Pivonello R ; Young J ; Hamrahian AH ; Molitch ME ; Shimizu C ; Tanaka T ; Shimatsu A ; White T ; Hilliard A ; Tian C ; Sauter N ; Biller BM ; Bertagna X Pituitary 2016[Apr]; 19 (2 ): 138-48 PMID26542280 show ga PURPOSE: In a 10-week proof-of-concept study (LINC 1), the potent oral 11?-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing's disease. The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cushing's disease. METHODS: Phase II, open-label, prospective study of two patient cohorts. Follow-up cohort: 4/12 patients previously enrolled in LINC 1, offered re-enrollment if baseline mean UFC was above ULN. Expansion cohort: 15 newly enrolled patients with baseline UFC > 1.5 × ULN. In the follow-up cohort, patients initiated osilodrostat twice daily at the penultimate efficacious/tolerable dose in LINC 1; dose was adjusted as needed. In the expansion cohort, osilodrostat was initiated at 4 mg/day (10 mg/day if baseline UFC > 3 × ULN), with dose escalated every 2 weeks to 10, 20, 40, and 60 mg/day until UFC ? ULN. Main efficacy endpoint was the proportion of responders (UFC ? ULN or ?50% decrease from baseline) at weeks 10 and 22. RESULTS: Overall response rate was 89.5% (n/N = 17/19) at 10 weeks and 78.9% (n/N = 15/19) at 22 weeks; at week 22, all responding patients had UFC ? ULN. The most common AEs observed during osilodrostat treatment were nausea, diarrhea, asthenia, and adrenal insufficiency (n = 6 for each). New or worsening hirsutism (n = 2) and/or acne (n = 3) were reported among four female patients, all of whom had increased testosterone levels. CONCLUSIONS: Osilodrostat treatment reduced UFC in all patients; 78.9% (n/N = 15/19) had normal UFC at week 22. Treatment with osilodrostat was generally well tolerated. |Administration, Oral [MESH] |Adrenocorticotropic Hormone/blood [MESH] |Adult [MESH] |Aged [MESH] |Enzyme Inhibitors/administration & dosage/adverse effects [MESH] |Female [MESH] |Follow-Up Studies [MESH] |Humans [MESH] |Hydrocortisone/urine [MESH] |Imidazoles/*administration & dosage/*adverse effects [MESH] |Male [MESH] |Middle Aged [MESH] |Pituitary ACTH Hypersecretion/blood/*drug therapy/urine [MESH] |Pyridines/*administration & dosage/*adverse effects [MESH]Osilodrostat, a potent oral 11?-hydroxylase inhibitor: 22-week, prospe(epmc).pdf DeepDyve Pubget Overpricing